Table 4.
Efficacy of other immunosuppressive agents in MOG-ab-positive children.
| Treatment modality | Number of patients on treatment for ≥6 months | Therapy duration (months) | Disease duration before administration of the therapy (months) | ARR before treatment | ARR during treatment | Change of ARR before and on treatment, % | Wilcoxon p value |
|---|---|---|---|---|---|---|---|
| RTX | 2 | 15 | 4 | 4 | 0 | 100 | 0.333 |
| 17 | 29 | 1.24 | 0.71 | 42.7 | |||
| MMF | 5 | 19 | 58 | 0.62 | 0.63 | −1.6 | 0.016 |
| 10 | 7 | 3.43 | 0 | 100 | |||
| 6 | 40 | 1.2 | 0 | 100 | |||
| 6 | 7 | 2 | 0 | 100 | |||
| 28 | 27 | 0.88 | 0 | 100 | |||
| AZA | 1 | 6 | 1 | 0 | 0 | / | / |
| Total, median (range) | 8 | 12.5 (6–28) | 17 (1–58) | 0 (0-4) | 0 (0-0.71) | 100 (-1.6-100) | 0.007 |
ARR, annualized relapse rate; AZA, azathioprine; MMF, mycophenolate mofetil; RTX, rituximab.
The Wilcoxon signed-rank test was used to identify differences between the ARR before treatment and on-treatment.